Indisulam

Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15[1][2].

Product Specifications

CAS Number

[165668-41-7]

Product Name Alternative

E 7070

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Carbonic Anhydrase; Molecular Glues

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Indisulam.html

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(S(=O)(N)=O)C=C1)(NC2=CC=CC3=C2NC=C3Cl)=O

Molecular Formula

C14H12ClN3O4S2

Molecular Weight

385.85

Precautions

H315, H319

References & Citations

[1]Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37 (17) :2275-82.|[2]Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14 (1) :217-23.